MacroChem
Executive Summary
Firm raised 53.4 mil. after expenses, from March offering of 690,000 units (two common shares and one warrant per unit). Firm has also decided to pursue development internally of a group of compounds with potential use as osteoporosis agents. The products had been licensed to Monsanto's Continental Pharma unit, but that firm subsequently relinquished the rights ("The Pink Sheet" May 27. p. 6).
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.